Related Experiment Video
Updated: Dec 8, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective
Gunther Marsche1, Gunnar H Heine2,3, Julia T Stadler1
1Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, 8010 Graz, Austria.
Insights
High-density lipoproteins (HDL) function, not just levels, impacts cardiovascular disease risk in chronic kidney disease (CKD). Understanding HDL changes in CKD is key to improving patient outcomes.
Area of Science:
- Cardiovascular Science
- Nephrology
- Lipid Metabolism
Background:
- Cardiovascular disease (CVD) is a major cause of mortality in chronic kidney disease (CKD) patients.
- Traditional risk factors do not fully explain the high CVD burden in CKD.
- High-density lipoproteins (HDL) are typically cardioprotective, but their role in CKD is complex and not fully understood.
Purpose of the Study:
- To review the current understanding of HDL composition, metabolism, and function in CKD.
- To explore the relationship between HDL properties and cardiovascular protection in CKD patients.
- To highlight knowledge gaps in HDL biology relevant to CKD.
Main Methods:
- Review of existing literature on HDL in CKD and cardiovascular disease.
- Focus on changes in HDL proteome and reverse cholesterol transport in CKD.
- Analysis of HDL subclasses and their functional impact.
Main Results:
- HDL cholesterol levels and cholesterol efflux capacity do not predict cardiovascular events in CKD patients.
- Impaired renal function alters HDL metabolism, composition, and functionality.
- CKD affects HDL's proteome and reverse cholesterol transport capacity, impacting its cardioprotective role.
Conclusions:
- HDL's role in cardiovascular protection is altered in CKD due to changes in its composition and function.
- Investigating specific HDL subclasses and their functions is crucial for understanding CVD in CKD.
- Further research is needed to fully elucidate HDL biology in the context of CKD.
Abstract:
In the general population, the ability of high-density lipoproteins (HDLs) to promote cholesterol efflux is a predictor of cardiovascular events, independently of HDL cholesterol levels. Although patients with chronic kidney disease (CKD) have a high burden of cardiovascular morbidity and mortality, neither serum levels of HDL cholesterol, nor cholesterol efflux capacity associate with cardiovascular events. Important for the following discussion on the role of HDL in CKD is the notion that traditional atherosclerotic cardiovascular risk factors only partially account for this increased incidence of cardiovascular disease in CKD. As a potential explanation, across the spectrum of cardiovascular disease, the relative contribution of atherosclerotic cardiovascular disease becomes less important with advanced CKD. Impaired renal function directly affects the metabolism, composition and functionality of HDL particles. HDLs themselves are a heterogeneous population of particles with distinct sizes and protein composition, all of them affecting the functionality of HDL. Therefore, a more specific approach investigating the functional and compositional features of HDL subclasses might be a valuable strategy to decipher the potential link between HDL, cardiovascular disease and CKD. This review summarizes the current understanding of the relationship of HDL composition, metabolism and function to their cardio-protective properties in CKD, with a focus on CKD-induced changes in the HDL proteome and reverse cholesterol transport capacity. We also will highlight the gaps in the current knowledge regarding important aspects of HDL biology.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Heart Failure Drugs: Diuretics
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

